SUNPHARMA vs THEMISMED: Stock Comparison

Sun Pharmaceutical Industries Ltd vs Themis Medicare Limited

Live data: 22 July 2026, 2:35 PM IST • Source: NSE and company filings

Sun Pharmaceutical Industries Ltd is the larger company by market capitalisation. Sun Pharmaceutical Industries Ltd shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Sun Pharmaceutical Industries Ltd and Themis Medicare Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, SUNPHARMA is more favourable on 11 of 13 scored metrics and THEMISMED on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SUNPHARMA is the larger company
₹4.66 L Cr vs ₹1,004 Cr
P/E Ratio
SUNPHARMA has a lower P/E
41.01x vs 938.33x
P/B Ratio
THEMISMED has a lower P/B
2.6x vs 5.63x
EPS
SUNPHARMA has higher earnings per share
₹47.87 vs ₹0.12
Dividend Yield
SUNPHARMA has a higher dividend yield
0.82% vs 0.43%
Revenue Growth (TTM YoY)
SUNPHARMA has faster revenue growth
12.8% vs 6.7%
EPS Growth (TTM YoY)
SUNPHARMA has faster EPS growth
25.6% vs 0%
Qtr Sales Growth
SUNPHARMA has stronger quarterly sales growth
12.8% vs 6.74%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricSUNPHARMATHEMISMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricSUNPHARMATHEMISMED
Live Price₹1,940₹108.25
Day Change-1.12%-3.65%
Volume13.13 L68,076
52-Week High₹1,966.5₹148
52-Week Low₹1,548₹64.95
Distance from 52W High-1.35%-26.86%

Valuation

MetricSUNPHARMATHEMISMED
Market Cap₹4.66 L Cr₹1,004 Cr
P/E Ratio41.01x938.33x
P/B Ratio5.63x2.6x
EPS₹47.87₹0.12
Book Value₹348.31₹43.06
Dividend Yield0.82%0.43%

Growth

MetricSUNPHARMATHEMISMED
Revenue Growth (TTM YoY)12.8%6.7%
EPS Growth (TTM YoY)25.6%0%
Qtr Sales Growth12.8%6.74%
Qtr Profit Growth13.6%192%

Profitability & Leverage

MetricSUNPHARMATHEMISMED
ROE16%0.29%
ROCE20.5%2.74%
Net Margin18.56%0.33%
Operating Margin28.2%-2.9%
Debt to Equity0.06x25.11x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricSUNPHARMATHEMISMED
Promoter Holding54.48%57.5%
FII Holding14.53% 1.4 pp0.11% 0.06 pp
DII Holding22.18% 1.07 pp0.01%
Public Holding8.81% 0.33 pp32.78% 0.05 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Sun Pharmaceutical Industries Ltd and Themis Medicare Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.